O investigation 2/115 HZ/su Data from trial of Herpes Zoster vaccine in the elderly 21115 Competitor Possible filing by Mytan for substitutible Advair generic 21116 Breo Results of SALFORD real world outcomes trial in COPO 2016 SNngrix File for regulatory approval for shingles vaccine 2016 C

prior period and modestly worse than assumed by consensus (23.2% Core EBIT vs consensus of 23.6%). This deterioration reflects pricing pressure on Advair and impact of the Novartis transaction. Management is now guiding to a c.500bp drag on margins for the FY partly as a result of greater than expect